Failure of right ventricular recovery of fallot patients after pulmonary valve replacement: delay of reoperation or surgical technique?

underwent monitoring during both the initial treatment and study drug discontinuation periods (n 5 163), ischemia was less frequently observed during both monitoring periods in the enoxaparin group (18.4% vs. 32.2%, p 5 0.045 and 25% vs. 46%, p 5 0.005, respectively). Further, the time to first ischemic episode was significantly earlier among UFH-treated patients, consistent with a superior early antithrombotic effect of enoxaparin and a reduction in the composite clinical end point of death, myocardial infarction (MI), and need for urgent revascularization (3). Therefore, we believe that enoxaparin has been shown to be superior to UFH based upon the consistent and statistically significant reductions in the composite and double (death/MI) end points in ESSENCE and TIMI 11B (4). In contrast, “extending the duration and slower weaning” of UFH is an unproven method of administration, and, in fact, the cost-savings realized with enoxaparin ultimately make it the less expensive option (5).